Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03292887 · ClinicalTrials.gov registry record
Hunter Outcome Survey (HOS)
A clinical trial of Hunter Syndrome, sponsored by Shire.
- Completed
- Registry status
- 1,443
- Enrollment target
- 1
- Study location
NCT03292887: Completed study of Hunter Syndrome, sponsored by Shire.
NCT03292887 is a study of Hunter Syndrome that has completed, run by Shire. The registered enrollment target is 1,443 participants, above the 68-participant average among 5 other Hunter Syndrome trials with a reported enrollment target (2022% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03292887, a study of Hunter Syndrome, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- 1,443 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to collect data that will increase understanding of Hunter syndrome. The data from HOS may provide guidance to healthcare professionals about disease treatment options.
Primary Outcome
An Infusion-related reaction (IRR) is an adverse event (AE) that occurs during or within 24 hours of an infusion and with evidence of a causal relationship with Elaprase.
Conditions Studied
Study Locations (1)
Massachusetts
- Shire - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,443 participants |
| Start Date | 2005-10-03 |
| Est. Completion | 2023-02-16 |
What the finished NCT03292887 record still lists
NCT03292887 is an observational study that tracks outcomes without assigning an intervention. Its 1,443 participants enrollment target places it among the larger protocols in the corpus, above the 68-participant average among 5 other Hunter Syndrome trials with a reported enrollment target (2022% higher).
The record links to 1 condition, with Hunter Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT03292887 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03292887 about?
NCT03292887 is a clinical study titled "Hunter Outcome Survey (HOS)". The purpose of this study is to collect data that will increase understanding of Hunter syndrome. The data from HOS may provide guidance to healthcare professionals about disease treatment options.
What is the current status of trial NCT03292887?
This trial is currently completed. The enrollment target is 1,443 participants. The study started on 2005-10-03. Estimated completion is 2023-02-16.
What conditions does trial NCT03292887 study?
This clinical trial studies the following conditions: Hunter Syndrome.
Who is sponsoring clinical trial NCT03292887?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03292887 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hunter Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis
ACTIVE NOT RECRUITING · Phase 2
-
An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
COMPLETED · Phase 1
-
A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®
COMPLETED · Phase 1
-
Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment
COMPLETED · Phase 2
-
Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04754022 · 1,440 participants · NA
Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery
- NCT04989790 · 1,440 participants · NA
Clinical Effectiveness of the "PICU Up!" Multifaceted Early Mobility Intervention for Critically Ill Children
- NCT06122246 · 1,440 participants · NA
PRESSURE CHECK: Find Your Path to Better Health
- NCT06324318 · 1,440 participants · Phase 2
Parenting in 2 Worlds Multisite Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI